Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
Seeking Alpha11/6/2026Neutral
DNA
Ginkgo Bioworks HoldingsNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$760.27M
P/E Ratio
—
EPS
$-4.24
Beta
1.74
52W High
$18.22
52W Low
$5.37
50-Day MA
$9.81
200-Day MA
$8.61
Dividend Yield
—
Profit Margin
-192.00%
Forward P/E
—
PEG Ratio
—
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Fundamentals
| Revenue (TTM) | $130.75M |
| Gross Profit (TTM) | $91.25M |
| EBITDA | $-235.23M |
| Operating Margin | -157.50% |
| Return on Equity | -58.20% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $2.15 |
| Book Value | $6.14 |
| Price-to-Book | 1.60 |
| Price-to-Sales (TTM) | 5.81 |
| EV/Revenue | 5.83 |
| EV/EBITDA | -1.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -28.60% |
| Shares Outstanding | $55.38M |
| Float | $47.52M |
| % Insiders | 4.56% |
| % Institutions | 74.62% |
Historical Volatility
HV 10-Day
190.60%
HV 20-Day
146.46%
HV 30-Day
157.20%
HV 60-Day
136.21%
HV Rank
99.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.00 target)
1
Hold1
Sell1
Strong SellLatest News
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Zacks Investment Research10/14/2026Negative
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
PRNewsWire10/8/2026Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
Zacks Investment Research10/7/2026Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.
Zacks Investment Research10/1/2026Negative
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
Zacks Investment Research9/23/2026Neutral
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research9/18/2026Positive
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
Zacks Investment Research9/16/2026Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
PRNewsWire5/26/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DNA and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026